- Home
- PRAX vs PAXS Comparison
PRAX vs PAXS Comparison
Compare PRAX & PAXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- PAXS
- Stock Information
- Founded
- PRAX 2015
- PAXS 2021
- Country
- PRAX United States
- PAXS United States
- Employees
- PRAX N/A
- PAXS N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- PAXS Investment Managers
- Sector
- PRAX Health Care
- PAXS Finance
- Exchange
- PRAX Nasdaq
- PAXS Nasdaq
- Market Cap
- PRAX 599.7M
- PAXS 717.7M
- IPO Year
- PRAX 2020
- PAXS N/A
- Fundamental
- Price
- PRAX $38.55
- PAXS $15.02
- Analyst Decision
- PRAX Strong Buy
- PAXS
- Analyst Count
- PRAX 10
- PAXS 0
- Target Price
- PRAX $116.50
- PAXS N/A
- AVG Volume (30 Days)
- PRAX 320.6K
- PAXS 195.0K
- Earning Date
- PRAX 05-02-2025
- PAXS 01-01-0001
- Dividend Yield
- PRAX N/A
- PAXS 11.72%
- EPS Growth
- PRAX N/A
- PAXS N/A
- EPS
- PRAX N/A
- PAXS N/A
- Revenue
- PRAX $8,122,000.00
- PAXS N/A
- Revenue This Year
- PRAX N/A
- PAXS N/A
- Revenue Next Year
- PRAX N/A
- PAXS N/A
- P/E Ratio
- PRAX N/A
- PAXS N/A
- Revenue Growth
- PRAX 270.02
- PAXS N/A
- 52 Week Low
- PRAX $26.70
- PAXS $12.57
- 52 Week High
- PRAX $91.83
- PAXS $15.93
- Technical
- Relative Strength Index (RSI)
- PRAX 53.72
- PAXS 47.73
- Support Level
- PRAX $35.21
- PAXS $14.58
- Resistance Level
- PRAX $38.90
- PAXS $15.32
- Average True Range (ATR)
- PRAX 2.09
- PAXS 0.20
- MACD
- PRAX 0.07
- PAXS -0.01
- Stochastic Oscillator
- PRAX 69.58
- PAXS 59.46
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About PAXS PIMCO Access Income Fund of Beneficial Interest
PIMCO Access Income Fund is a non-diversified, limited-term, closed-end management investment company. The fund seeks current income as an objective and capital appreciation as a secondary objective. It achieves the investment objectives by utilizing a dynamic asset allocation among multiple sectors in the public and private credit markets, including corporate debt.